<DOC>
	<DOCNO>NCT02576990</DOCNO>
	<brief_summary>In study , participant relapse refractory primary mediastinal large B-cell lymphoma ( rrPMBCL ) relapse refractory Richter Syndrome ( rrRS ) receive pembrolizumab ( MK-3475 ) . The efficacy pembrolizumab treatment rrPMBCL rrRS evaluate .</brief_summary>
	<brief_title>Study Pembrolizumab ( MK-3475 ) Participants With Relapsed Refractory Primary Mediastinal Large B-cell Lymphoma Relapsed Refractory Richter Syndrome ( MK-3475-170/KEYNOTE-170 )</brief_title>
	<detailed_description>Treatment pembrolizumab continue maximum 35 administration ( approximately 2 year ) document disease progression investigator assessment , unacceptable adverse event ( ) ( AEs ) , intercurrent illness prevents administration treatment , participant withdraws consent , pregnancy participant , noncompliance study treatment procedure requirement , administrative reason .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Pembrolizumab</mesh_term>
	<criteria>PMBCL : Diagnosis relapse refractory primary mediastinal large Bcell lymphoma . Previously expose rituximab part prior line treatment . RS : Pathologic diagnosis per local institutional review Richter syndrome transform CLL . Relapsed refractory Richter syndrome receive ≥1 previous treatment RS . All Participants : Radiographically measureable disease . Performance status 0 1 Eastern Cooperative Oncology Group ( ECOG ) Performance Scale . Life expectancy &gt; 3 month . Adequate organ function . Female participant childbearing potential must willing use adequate method contraception course study 120 day last dose study drug . Male participant childbearing potential must agree use adequate method contraception , start first dose study drug 120 day last dose study drug . Is currently participate receive study therapy participate study investigational agent receive study therapy use investigation al device within 4 week first dose study drug . Is receive systemic steroid therapy &lt; 3 day first dose study drug receive form immunosuppressive medication . Known history immunosuppression receive systemic steroid therapy form systemic immunosuppressive therapy within 7 day prior first dose study drug . Prior monoclonal antibody within 4 week prior study Day 1 ( 2 week RS participant ) recover ( i.e . ≤ Grade 1 baseline ) adverse event due agent administer 4 week earlier ( 2 week RS participant ) . Prior chemotherapy target small molecule therapy within 2 week prior study Day 1 prior radiation therapy within 4 week prior study Day 1 . Allogeneic hematopoietic stem cell transplantation within last 5 year . Has know additional malignancy ( except underlie CLL RS ) progress require active treatment . Exceptions include basal cell carcinoma skin , squamous cell carcinoma skin , situ cervical cancer undergone potentially curative therapy . Known clinically active central nervous system involvement . Active autoimmune disease require systemic treatment past 2 year . History ( noninfectious ) pneumonitis require steroid , current pneumonitis . Active infection require intravenous systemic therapy . Is pregnant breastfeeding , expect conceive father child within project duration study , start prescreening screen visit 120 day last dose study drug . Has receive prior therapy antiprogrammed cell death 1 ( antiPD1 ) , antiprogrammed cell death ligand 1 ( antiPDL1 ) , antiPDL2 , antiCD137 , anticytotoxic Tlymphocyteassociated antigen4 ( CTLA4 ) antibody ( include ipilimumab antibody drug specifically target Tcell costimulation checkpoint pathway ) . Known human immunodeficiency virus ( HIV ) , Hepatitis B C. Has receive live vaccine within 30 day prior first dose study drug .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>PD1</keyword>
	<keyword>PD-1</keyword>
	<keyword>PDL1</keyword>
	<keyword>PD-L1</keyword>
</DOC>